Interleukin Modulators
Pharmacology of drugs targeting interleukins including IL-1, IL-6, IL-17, IL-23, IL-4/13, and IL-5 -- mechanisms, indications, and clinical outcomes.
## Interleukin Signaling in Disease
Interleukins (ILs) are cytokines that mediate communication between immune cells. Dysregulated interleukin signaling drives pathology in autoimmune, allergic, and autoinflammatory diseases. Targeting specific interleukins allows precision immunomodulation with narrower side effect profiles than broad immunosuppression.
Over 40 interleukins have been identified, but pharmacological targeting has focused on those with validated roles in human disease.
## IL-1 Pathway Inhibitors
IL-1alpha and IL-1beta are master pro-inflammatory cytokines produced via inflammasome activation. Three approved agents target this pathway:
- **Anakinra**: Recombinant IL-1 receptor antagonist (IL-1Ra). Daily subcutaneous injection. Used in rheumatoid arthritis, cryopyrin-associated periodic syndromes (CAPS), and gout flares
- **Canakinumab**: Anti-IL-1beta monoclonal antibody. Every 8 weeks. Approved for CAPS, systemic juvenile idiopathic arthritis, and gout. CANTOS trial showed cardiovascular benefit independent of lipid lowering
- **Rilonacept**: IL-1 Trap (soluble decoy receptor). Weekly. Used in CAPS and recurrent pericarditis
## IL-6 Pathway Inhibitors
IL-6 drives acute-phase responses, CRP production, and Th17 differentiation. **Tocilizumab** and **sarilumab** block the IL-6 receptor (anti-IL-6R), while **siltuximab** binds IL-6 directly. Tocilizumab is approved for rheumatoid arthritis, giant cell arteritis, cytokine release syndrome (CAR-T complication), and COVID-19 pneumonia with systemic inflammation.
IL-6 blockade suppresses CRP and ferritin, which can mask infection signs -- clinicians must rely on clinical assessment rather than inflammatory markers during treatment.
## IL-17 and IL-23 Inhibitors
The IL-23/IL-17 axis drives psoriasis, psoriatic arthritis, and ankylosing spondylitis. **Secukinumab** and **ixekizumab** neutralize IL-17A. **Brodalumab** blocks the IL-17 receptor. **Guselkumab**, **risankizumab**, and **tildrakizumab** target the p19 subunit of IL-23, which is upstream of Th17 differentiation. IL-23 inhibitors demonstrate superior durability in psoriasis with less frequent dosing.
## IL-4/13 and IL-5 Inhibitors
**Dupilumab** blocks IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signaling. It is approved for atopic dermatitis, asthma (eosinophilic/oral corticosteroid-dependent), and chronic rhinosinusitis with nasal polyps. **Mepolizumab**, **reslizumab**, and **benralizumab** target the IL-5 pathway to reduce eosinophil counts in severe eosinophilic asthma.
## Key Takeaways
- Each interleukin pathway maps to distinct disease phenotypes, enabling precision targeting
- IL-6 blockade masks CRP and fever, requiring altered infection monitoring
- IL-23 inhibitors offer upstream control of the Th17 axis with durable responses
- IL-4/13 and IL-5 blockade transformed management of type 2 inflammatory diseases